US listed Healthcare Players on Vaccine Development for COVID-19

June 19, 2020 02:57 PM AEST | By Team Kalkine Media
Follow us on Google News:

Several healthcare companies and researchers across the globe are burning the midnight oil for finding a safe and effective vaccine/treatment for deadly novel coronavirus.

Meanwhile, some concerns related to a second wave have triggered a global dilemma. Some studies have demonstrated recently that the novel coronavirus not only affects human lugs, it can also penetrate to other organs of the human body.

Experts stated that the novel coronavirus could infect the human brain and replicate small neuronal spheres called as 'mini-brains' growing ten times within three days. Nevertheless, until now, it is not clear whether the virus causes the brain infection or is it due to any other secondary damage.

At present, there is an urgent need for a vaccine or treatment for this deadly virus which has created havoc around the world.

Today, lets discuss five US-listed healthcare companies which are engaged in the development of COVID-19 vaccine:

Sinovac Biotech

China-based leading provider of biopharmaceutical products, Sinovac Biotech Ltd (NASDAQ:SVA) is focused on the R&D, manufacturing as well as commercialisation of vaccine for infectious diseases with significant unmet medical needs.

Sinovac is developing a vaccine named as CoronaVac that uses an inactive SARS-CoV-2 to generate an immune response against the active version of the virus.


UK-based global science-led biopharmaceutical company AstraZeneca plc (NASDAQ:AZN) is into the discovery, development as well as commercialisation of prescription drugs, mainly for the treatment of ailments in the therapy areas of Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.


On 15 June 2020, Novavax disclosed that the Company had signed an agreement to sell Series A Convertible preferred stock, convertible into approximately 4,388,852 shares of common stock, to an RA Capital Management investment fund in a private placement, at an effective purchase price per share of common stock equal to the closing price on 12 June 2020. Upon closing, Novavax will receive gross proceeds of approximately US$200 million.

#US #COVID19 #VACCINE #Research #Kalkine


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK